Savara (SVRA) Preferred Stock Liabilities (2014 - 2016)
Savara (SVRA) posted quarterly Preferred Stock Liabilities of $43.9 million for Q4 2016, up 2.04% year-over-year from $43.0 million in Q1 2016, and up 2.04% quarter-over-quarter from $43.0 million in Q4 2015.
Savara (SVRA) Preferred Stock Liabilities (2014 - 2016) Analysis & Trends
Savara (SVRA) has reported Preferred Stock Liabilities for 3 consecutive years, with $43.9 million the latest figure, recorded in Q4 2016.
- In Q4 2016, Preferred Stock Liabilities rose 2.04% year-over-year to $43.9 million; the TTM figure through Dec 2016 stood at $43.9 million (up 2.04% YoY), while the FY2016 annual figure was $43.9 million, up 2.04% from the prior year.
- Preferred Stock Liabilities advanced to $43.9 million in Q4 2016 per SVRA's latest filing, from $43.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $43.9 million in Q4 2016 and bottomed at $20.3 million in Q4 2014.
- Historically, Preferred Stock Liabilities has averaged $35.7 million across 3 years, with a median of $43.0 million in 2015.
- Annual changes were most pronounced in 2015 — Preferred Stock Liabilities soared 112.05% — and 2016, when it gained 2.04%.
- Savara's Preferred Stock Liabilities stood at $20.3 million in 2014, then surged by 112.05% to $43.0 million in 2015, then gained by 2.04% to $43.9 million in 2016.
- Business Quant data shows SVRA's Preferred Stock Liabilities at $43.9 million in Q4 2016, $43.0 million in Q4 2015, and $20.3 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 43.86 Mn |
| Dec 31, 2015 | 42.99 Mn |
| Dec 31, 2014 | 20.27 Mn |